Literature DB >> 6187848

Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: determination of affinities and specificities of monoclonal antibodies by using biotin-labeled antibodies and avidin as precipitating agent in a solution phase immunoassay.

C Wagener, B R Clark, K J Rickard, J E Shively.   

Abstract

A general method is described for the determination of affinity constants and antigen cross-reactivities of monoclonal antibodies. The method employs biotin-labeled antibody, radiolabeled antigen, and avidin as a precipitating agent in a homogeneous phase, competitive radioimmunoassay. This method eliminates incomplete or variable precipitation of antigen-antibody complexes often encountered in immunoassays in which monoclonal antibodies are employed. Using this assay system, we were able to rapidly determine the affinity constants for a number of monoclonal antibodies elicited to carcinoembryonic antigen (CEA). In the preceding paper it was shown that five of the monoclonal antibodies recognized distinct epitopes on CEA. In antigen-binding experiments with these five monoclonal antibodies, the percent of radiolabeled CEA bound in antibody excess ranged from 30 to 92%. The CEA cross-reacting antigens, normal cross-reacting antigen (NCA), and tumor-extracted, CEA-related antigen (TEX) were significantly bound by one, and to a lesser degree, by two of the five antibodies. Two antibodies did not bind significant amounts of NCA or TEX. In inhibition studies, the amount of unlabeled CEA leading to 50% inhibition of 125I-labeled CEA-binding was in the range of 3.7 to 760 ng per tube. The amount of TEX showing the same degree of inhibition was 23-fold greater than the amount of CEA for two antibodies and 351-fold greater than the amount of CEA for a third antibody. The affinity constants for CEA were in the range of 1.0 x 10(8) to 5.1 x 10(10) M-1. The affinity constants for NCA and TEX, determined for one of the antibodies, were three orders of magnitude lower in comparison to CEA. The heterogeneity of radiolabeled CEA as indicated by the low fraction bound by one of the monoclonal antibodies is shown to be most probably an artifact resulting from radioiodination damage. The application of the approach described in this report should eliminate the problems most commonly encountered in the determination of affinity constants for monoclonal antibodies or the use of monoclonal antibodies in competitive, homogeneous-phase immunoassays.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6187848

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.

Authors:  Joseph Ryan Polli; Frank A Engler; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2018-10-12       Impact factor: 3.534

2.  Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity.

Authors:  H P Roost; M F Bachmann; A Haag; U Kalinke; V Pliska; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

3.  A transition metal complex (Venus flytrap cluster) for radioimmunodetection and radioimmunotherapy.

Authors:  R J Paxton; B G Beatty; M F Hawthorne; A Varadarajan; L E Williams; F L Curtis; C B Knobler; J D Beatty; J E Shively
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  cis Interaction of the cell adhesion molecule CEACAM1 with integrin beta(3).

Authors:  J Brümmer; A Ebrahimnejad; R Flayeh; U Schumacher; T Löning; A M Bamberger; C Wagener
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  CEACAM1 enhances invasion and migration of melanocytic and melanoma cells.

Authors:  Alireza Ebrahimnejad; Thomas Streichert; Peter Nollau; Andrea K Horst; Christoph Wagener; Ana-Maria Bamberger; Jens Brümmer
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

6.  Mutational analysis of the cytoplasmic domain of CEACAM1-4L in humanized mammary glands reveals key residues involved in lumen formation: stimulation by Thr-457 and inhibition by Ser-461.

Authors:  Chunxia Li; Charng-Jui Chen; John E Shively
Journal:  Exp Cell Res       Date:  2008-12-30       Impact factor: 3.905

7.  Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli.

Authors:  S Cabilly; A D Riggs; H Pande; J E Shively; W E Holmes; M Rey; L J Perry; R Wetzel; H L Heyneker
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

Review 8.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Regulation of CEACAM1 transcription in human breast epithelial cells.

Authors:  Marieta Gencheva; Charng-Jui Chen; Tung Nguyen; John E Shively
Journal:  BMC Mol Biol       Date:  2010-11-04       Impact factor: 2.946

10.  CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation.

Authors:  George A Abou-Rjaily; Sang Jun Lee; Denisa May; Qusai Y Al-Share; Anthony M Deangelis; Randall J Ruch; Michael Neumaier; Holger Kalthoff; Sue-Hwa Lin; Sonia M Najjar
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.